fbpx

 Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia

LONDON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) is reimbursed in Australia for people with cystic fibrosis (CF) ages

Read more

Alexion Receives FDA Approval for ULTOMIRIS® (ravulizumab-cwvz) for Atypical Hemolytic Uremic Syndrome (aHUS)

– At 26 weeks, 54% of adults and 71% of children treated with ULTOMIRIS demonstrated Complete Thrombotic Microangiopathy (TMA) Response – BOSTON–(BUSINESS WIRE)–Alexion Pharmaceuticals,

Read more

Opioid Overdose Pipeline Report, 2019 Insights – Treatment Patterns, Analytical Perspective, Pipeline Therapeutics, Products Analysis, Technologies, Key Companies – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Opioid Overdose – Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. Opioid Overdose – Pipeline Insight, 2019 report outlays

Read more

Ichthyosis Pipeline Insights 2019 – Key Players are Mayne Pharma/Galderma (Trifarotene), Patagonia Pharmaceuticals (PAT-001), Exicure (XCUR 17) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Ichthyosis- Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. Ichthyosis-Pipeline Insight, 2019 report outlays comprehensive insights of present scenario

Read more

Fanconi Anemia (FA) Pipeline Insight, 2019 Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Fanconi Anemia (FA) – Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. Fanconi Anemia (FA) – Pipeline Insight, 2019

Read more